Changeflow GovPing Pharma & Drug Safety Polycyclic Compound for Treatment of Abnormal C...
Routine Notice Added Final

Polycyclic Compound for Treatment of Abnormal Cell Proliferation Diseases

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260098043A1 disclosing a polycyclic compound (CLM-L-PTM) or its pharmaceutical salt for treating abnormal cell proliferation diseases. The application names five inventors and covers pharmaceutical compositions suitable for preparing drugs targeting cell proliferation disorders.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO published application US20260098043A1 disclosing a novel polycyclic compound designated CLM-L-PTM, including pharmaceutically acceptable salts and pharmaceutical compositions. The invention targets abnormal cell proliferation diseases, classified under CPC codes including C07D 495/14 and A61P 35/00 (antineoplastic activity). The application was filed on September 13, 2023.

Pharmaceutical companies developing oncology or anti-proliferative therapies should review this patent for potential freedom-to-operate concerns or licensing opportunities. The broad claim scope covering multiple heterocyclic systems and treatment applications may overlap with existing research programs in this therapeutic area.

What to do next

  1. Monitor patent portfolio for competitive implications
  2. Review composition claims for potential licensing opportunities

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

POLYCYCLIC COMPOUND AND USE THEREOF

Application US20260098043A1 Kind: A1 Apr 09, 2026

Inventors

Jinghai JIN, Yuewen LI, Yu SHI, Wei ZHU, Zhengtao LI

Abstract

A compound represented by formula (I) CLM-L-PTM or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof, which are particularly suitable for preparing drugs for treating or preventing abnormal cell proliferation diseases.

CPC Classifications

C07D 495/14 A61K 31/454 A61K 31/5377 A61K 31/5517 A61K 31/553 A61K 31/675 A61P 35/00 C07D 401/04 C07D 401/14 C07D 413/04 C07D 413/14 C07D 417/14 C07D 487/14 C07D 487/16 C07D 498/04 C07D 498/08 C07D 519/00 C07F 9/65583

Filing Date

2023-09-13

Application No.

19111594

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098043A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Pharmaceutical research Drug development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!